With Cephalon Deal, Teva Sees Opportunities For Niche Branded Drugs and Drug/Device Combinations
This article was originally published in The Pink Sheet Daily
Executive Summary
While the value of Cephalon's pipeline is "modest," the specialty pharma will provide Teva with an expanded portfolio of marketed branded drugs, commercial infrastructure and cost synergies, making integration execution critical.
You may also be interested in...
Deal Watch: After Novartis Deal, GSK Increases Vaccine Emphasis With GlycoVaxyn Buyout
Sanofi moves into ROR gamma T R&D for potential autoimmune therapies in collaboration with Lead Pharma, while Intrexon acquires Belgium’s ActoGeniX and its platform technology for creating a novel class of biotherapeutics targeting the oral and GI tracts. Teva heads off dispute with Eagle, bringing in new bendamustine formulation.
Teva, CRT Build On Tie That Produced aPKC Protein Inhibitor Candidate
By jointly finding a first-in-class atypical Protein Kinase C inhibitor preclinical candidate, Israel’s Teva and Britain’s Cancer Research Technology have successfully capped a four-year collaboration and are now branching out into the area of DNA damage response.
Mesoblast Advances Stem-Cell Drugs As Catalysts Approach
Australian regenerative medicines company Mesoblast is working with its partner Teva to move a stem-cell treatment for congestive heart failure into Phase III clinical studies.